Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04146441
Other study ID # 040376MH
Secondary ID 2019-001736-57
Status Completed
Phase Phase 2
First received
Last updated
Start date February 10, 2020
Est. completion date December 31, 2022

Study information

Verified date January 2023
Source St. Olavs Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with inoperable pancreatic cancer have extremely poor prognosis with five year survival below 8% in Norway. Life-prolonging chemotherapy has very limited effect, but is the only therapeutic option for these patients. This tumor is characterized by poor uptake and chemoresistance. Toxic effects on healthy tissue restrict doses applied and maintenance of treatment intensity. This severely limits clinical outcome. Increasing the local uptake of chemotherapy has potential benefits for patients in connection to side effects, survival and possible cure. Treatment with Focused Ultrasound (FUS) combined with microbubbles (MBs) is proved promising to improve treatment response in animal and clinical trials. Ultrasound can induce biological effects deep inside the body without surgical intervention. This opens for local delivery of drugs at desired sites. FUS in combination with regular contrast MBs has been reported to influence the delivery of drugs to tumors. In this trial FUS and MB will be applied to locally advanced pancreatic cancers shortly after the administration of conventional chemotherapy. Primary aim of the trial is to investigate whether the effect of the cytostatic drug, measured in tumor volume, can be increased.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers No
Gender All
Age group 19 Years to 89 Years
Eligibility Inclusion Criteria: - Radiologically verified stage III or IV PDAC or medically inoperable stage IIB T3 PDAC - eligible for 1st line treatment with FOLFIRINOX, Gemcitabine -nab Paclitaxel, or Gemcitabine monotherapy. - ECOG 0 - 1 Exclusion Criteria: - Known contraindications for SonoVue - Hematological bleeding status before experimental treatment: - Hb < 8g/dL, trc < 80 x10 superscr 9/l, APTT? 45s, INR ? 1,5 - Pregnancy

Study Design


Related Conditions & MeSH terms


Intervention

Combination Product:
SonoVue
1,0 ml SonoVue 8ul/ml dispersion is given 9 times at 3,5 minute intervals 9 times, a total dosage of 9 ml. The experimental treatment lasts for 31,5 minutes every treatment day. Administered by authorized site personnel only
Drug:
Chemotherapy
FOLFIRINOX Regime according to Norwegian national guidelines

Locations

Country Name City State
Norway Department of Radiology, St Olavs Hospital Trondheim

Sponsors (2)

Lead Sponsor Collaborator
St. Olavs Hospital Norwegian University of Science and Technology

Country where clinical trial is conducted

Norway, 

Outcome

Type Measure Description Time frame Safety issue
Primary Volume change of primary tumor measured by segmented tumor volumes on Computed Tomography of primary PDAC tumor from before treatment (baseline) to after 1 cycle of treatment 8 weeks
Secondary Number of down-staged tumors from stage III to stage II 8 weeks
Secondary Number of down-staged tumors from stage III to stage II 1 year
Secondary Rate of reported toxicity Toxicity reported by patients during structured interview after treatment. Type of side effects and severity according to Common Toxicity Criteria (CTC) 8 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT03500068 - Establishing Organoids From Metastatic Pancreatic Cancer Patients, the OPT-I Study. N/A
Not yet recruiting NCT05489458 - Predictive Factors for Resection and Survival in Type A Borderline Resectable Pancreatic Ductal Adenocarcinoma Patients After Neoadjuvant Therapy
Recruiting NCT02310230 - An Evaluation of the Utility of the ExSpiron Respiratory Variation Monitor During Upper GI Endoscopy N/A
Completed NCT01478685 - A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors Phase 1
Completed NCT03513705 - Impact of Nationwide Enhanced Implementation of Best Practices in Pancreatic Cancer Care (PACAP-1) N/A
Completed NCT01808638 - Atu027 Plus Gemcitabine in Advanced or Metastatic Pancreatic Cancer (Atu027-I-02) Phase 1/Phase 2
Withdrawn NCT00226746 - Efficacy Study of Gemcitabine, Paclitaxel, and Irradiation in the Treatment of Pancreatic Cancer Phase 2
Not yet recruiting NCT03432624 - Detection of MicroRNA-25 in the Diagnosis of Pancreatic Cancer N/A
Recruiting NCT02451384 - According CTC to Compare the Influences of Different Methods to Remove the PDAC N/A
Recruiting NCT02529579 - Safety and Efficacy Evaluation of iAPA-DC/CTL Combined Gemcitabine Therapy on Advanced Pancreatic Cancer Phase 1/Phase 2
Not yet recruiting NCT06447662 - A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. Phase 1
Recruiting NCT02817308 - Correlation of Serum CA19-9 Levels With Levels in Saliva and Urine of Patients With Ductal Adenocarcinoma of the Pancreas N/A
Completed NCT00471146 - Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine For Advanced Pancreatic Cancer. Phase 3
Recruiting NCT05461430 - Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
Terminated NCT01413451 - Amatuximab for High Mesothelin Cancers Early Phase 1
Recruiting NCT03403101 - The Combination Chemotherapy of SIRIOX as First- or Second-Line Chemotherapy for Pancreatic Cancer Phase 2
Recruiting NCT02928081 - Standard Versus Extended Lymphadenectomy in Pancreatoduodenectomy for Patients With Pancreatic Head Adenocarcinoma N/A
Completed NCT05723978 - Selective Extended Dissection in Different Types of Pancreatic Head Cancer: A Retrospective Cohort Study.
Completed NCT02150746 - Circulating Tumor Cells in Operative Blood N/A
Not yet recruiting NCT05621824 - A Cohort Study on Screening and Follow-up of High-risk Population of PDAC Based on EUS